Kinesin Inhibitor

ALN-12115 sodium is a siRNA that targets kinesin spindle protein (KSP), and it is one of the siRNAs in ALN-VSP.ALN-VSP is a lipid nanoparticle formulation containing two siRNAs for KSP and VEGF with potential antitumor activity.

SCH 2047069 (MK-8267) is an orally active kinesin spindle protein (KSP) inhibitor (K_d: 0.5 nM) that can cross the blood-brain barrier. SCH 2047069 exhibits an IC₅₀ value of ≤ 5 nM against the KSP ATPase. SCH 2047069 exhibits broad-spectrum antitumor activity. SCH 2047069 can induce mitotic arrest and apoptosis in tumor cells. SCH 2047069 can be used in the research of tumors such as ovarian cancer, colon cancer, glioblastoma, and lymphoma.

KIF18A-IN-20 is an orally active KIF18A inhibitor with an IC₅₀ of 52 nM. KIF18A-IN-20 targets the plus-end-directed mitotic kinesin KIF18A, regulating chromosome alignment and spindle dynamics, and inhibits the proliferation of chromosomally unstable OVCAR-3 ovarian cancer cells with EC₅₀ = 3.4 nM. KIF18A-IN-20 achieves tumor regression in xenograft models without causing body weight loss. KIF18A-IN-20 can be used for research related to ovarian cancer.

Kif12 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Kif12 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

KIF18A-IN-11 (Compound 13) is a potent KIF18A inhibitor, with IC₅₀ values of less than 100 nM in OVCAR3 and MDA-MB-157 cells. KIF18A-IN-11 can be used for the research of cancer.

KIF11 Human Pre-designed siRNA Set A contains three designed siRNAs for KIF11 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Kif12 Rat Pre-designed siRNA Set A contains three designed siRNAs for Kif12 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

KIF12 Human Pre-designed siRNA Set A contains three designed siRNAs for KIF12 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LG157 is a potent inhibitor of mitotic kinesin-like protein 2 (MKLP2).

SeSA-HCPT is an orally active dual-target inhibitor integrating Topo I and HDAC inhibition. SeSA-HCPT induces potent DNA damage, apoptosis, S-phase arrest in prostate cancer cells. SeSA-HCPT inhibits cancer cells proliferation and migration. SeSA-HCPT impairs homologous recombination by suppressing KIF4A-RAD51 signaling. SeSA-HCPT markedly inhibits CRPC tumor growth with minimal systemic toxicity.

Anticancer agent 190 (compound 3e) is an inhibitor targeting KSP (Kinesin) and PI3Kδ with activity against breast cancer.

EX05 is a potent KIF18A inhibitor with an IC₅₀ value of 8.2 nM. EX05 has the potential for the research of cancer.

KIF18A-IN-19 (Compound 1) is an orally active KIF18A inhibitor with an IC₅₀ of <0.1 μM. KIF18A-IN-19 has anti-cancer activity against ovarian cancer.

KIF18A-IN-12 (compound 9) is a KIF18A inhibitor, with an IC₅₀ value of 45.54 nM. KIF18A-IN-12 can be used in cancer research.

KIF18A-IN-14 (Compound Example 81) is a KIF18A inhibitor. KIF18A-IN-14 is available in two forms, EX81-A and its enantiomer EX81-B. EX81-A and EX81-B inhibit OVCAR-3 cells viability with IC₅₀s of 0-0.01 μM and 0.01-0.1 μM, respectively. KIF18A-IN-14 can be used in tumor (e.g. colon, breast, lung) studies.

CENP-E-IN-2 (compound 3) is a photoswitchable CENP-E inhibitor, with the pIC₅₀ of 6.82 without light illumination and 5.85 with 365 nm light illumination. CENP-E-IN-2 has antitumor activity.

KIF18A-IN-10 (Compound 24) is a potent KIF18A inhibitor, with an IC₅₀ value of 23.8 nM. KIF18A-IN-10 has anticancer activity, with IC₅₀ values of less than 100 nM in OVCAR3 and MDA-MB-157 cells.

KSP-IA (compound 17) is a potent kinesin spindle protein (KSP) inhibitor with an IC₅₀ value of 3.6 nM. KSP-IA inhibits cell mitosis.

KIF6 Human Pre-designed siRNA Set A contains three designed siRNAs for KIF6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CENP-E-IN-1 is a CENP-E inhibitor. CENP-E-IN-1 acts as a Mitotic arrest inducer and Apoptosis inducer, which causes abnormal alignment of chromosomes on the metaphase plate, activates the spindle assembly checkpoint and triggers apoptosis. CENP-E-IN-1 exhibits anti-tumor activity in colorectal adenocarcinoma xenograft models. CENP-E-IN-1 can be used in cancer-related research.